Skip to main content
Equibles
ARQT logo

ARQT · Arcutis Biotherapeutics, Inc. · Investor Relations

Track ARQT — free

Use ARQT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ARQT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$28.26 +0.73 (+2.65%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$3.57B
Shares
126.46M
Volume · Nov 13 858.23K Avg daily vol (3M) 2.62M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-11-13 Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% f
2026-11-06 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-05 Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Se
2026-11-04 Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update
2026-10-28 Arcutis Appoints Rob Scott, MD to Board of Directors
2026-10-27 Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
2026-10-21 Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026
2026-10-09 Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV a
2026-10-06 Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
2026-08-05 Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
2026-07-16 Arcutis Expands Board of Directors with Appointment of Chris Peetz
2026-02-25 Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2025-12-08 Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri

Past events

Date Event Type
2026-11-10 Guggenheim 3rd Annual Healthcare Innovation Conference Conference
2026-11-04 Arcutis Biotherapeutics, Inc. Q3 2026 Earnings Conference Call Earnings call
2026-09-16 Morgan Stanley 24th Annual Global Healthcare Conference Conference
2026-08-05 Arcutis Biotherapeutics, Inc. Q2 2026 Earnings Conference Call Earnings call
2026-06-09 Goldman Sachs 47th Annual Global Healthcare Conference Conference
2026-05-06 Arcutis Biotherapeutics, Inc. Q1 2026 Earnings Conference Call Earnings call
2026-04-14 25th Annual Needham Virtual Healthcare Conference Conference
2026-03-02 TD Cowen 46th Annual Health Care Conference Conference
2026-02-25 Arcutis Biotherapeutics, Inc. Q4/FY 2025 Earnings Conference Call Earnings call
2026-02-11 Guggenheim Emerging Outlook: Biotech Summit Event
2025-11-12 TD Cowen Immunology & Inflammation Summit Event
2025-11-11 Guggenheim’s 2nd Annual Healthcare Innovation Conference Conference
2025-10-28 Arcutis Virtual Investor Day and Third Quarter 2025 Earnings Conference Call Earnings call
2025-08-06 Arcutis Biotherapeutics, Inc. Q2 2025 Earnings Conference Call Earnings call

Source: https://investors.arcutis.com/

Key facts CIK 1787306 CUSIP 03969K108 13F (30d) 222 filings 200 filers Visit website Investor relations